Clinical Trial: Subcuteous Methotrexate in Rheumatoid Arthritis

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07094880) titled 'Subcuteous Methotrexate in Rheumatoid Arthritis' on May 29.

Brief Summary: Methotrexate use is important for the treatment of Rheumatoid arthritis. Some patients can not tolerate oral methotrexate. So subcutaneous may help to overcome it.

Study Start Date: June 01, 2015

Study Type: INTERVENTIONAL

Condition: Methotrexate Adverse Reaction Advantage of Using Subcutaneous Route for Methotrexate

Intervention: DRUG: Tab. Methotrexate 25mg/week

Tab. Methotrexate will be given orally in one arm at a dose of 25 mg/week

DRUG: Inj. Methotrexate 25mg/week

Inj. Methotrexate 25 mg/week will be given subcutaneously in another arm

Recruit...